BAM
CADL icon

Belpointe Asset Management’s Candel Therapeutics CADL Stock Holding History

Belpointe Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Buy
52,778
+7,174
+16% +$54.2K 0.02% 700
2026
Q1 		$223K Buy
+45,604
New +$248K 0.01% 968

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Belpointe Asset Management's CADL Position: Q2 2026 in Review

Belpointe Asset Management increased its Candel Therapeutics (CADL) stake by 16% in Q2 2026, buying an estimated $54.2K and bringing the position to 52,778 shares worth $544K. The position accounts for 0.02% of the portfolio, ranked #700.

Belpointe Asset Management first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Belpointe Asset Management held 52,778 shares of Candel Therapeutics worth $544K as of Q2 2026.
  • Belpointe Asset Management bought 7,174 Candel Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Candel Therapeutics made up 0.02% of Belpointe Asset Management's portfolio in Q2 2026, its #700 holding.
  • Belpointe Asset Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.